BME:PHMBiotechs
Assessing Pharma Mar (BME:PHM) Valuation After BBB Credit Rating Upgrade
Pharma Mar (BME:PHM) just received a long term credit rating upgrade to BBB with a stable outlook, a shift that could influence how you view its funding options and growth capacity.
See our latest analysis for Pharma Mar.
The rating upgrade lands at a time when momentum in the share price is already strong, with a 30 day share price return of 17.97% and a year to date share price return of 21.60%. The 3 year total shareholder return of 130.23% points to a materially different experience for...